Role of polymorphic human cytochrome P450 enzymes in estrone oxidation

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 3, 2006, Pages 551-558

  Cribb, Alastair E ^a   Knight, M Joy ^a   Dryer, Dagny ^b   Guernsey, Judy ^c   Hender, Kimberly ^b   Tesch, Marvin ^b   Saleh, Tarek M ^a  

^a UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

^b Prince Edward Island   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; 4 HYDROXYESTRONE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2C19; CYTOCHROME P450 3A5; ESTRONE;

ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; ENZYME ACTIVITY; ESTROGEN METABOLISM; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYDROXYLATION; IN VITRO STUDY; LIVER MICROSOME; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT;

BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ESTRONE; FEMALE; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 33645518818     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0801     Document Type: Article

References (68)

1. Liehr JG. Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 1997;6:3-10.
2. Zumoff B. Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy. Proc Soc Exp Biol Med 1998; 217:30-7.
3. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352:93-7.
4. Russo J, Hasan Lareef M, Balogh G, Guo S, Russo IH. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol 2003;87:1-25.
5. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;36:203-32.
6. Liehr JG, Fang WF, Sirbasku DA, Ari-Ulubelen A. Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem 1986;24:353-6.
7. Cavalieri EL, Rogan EG. A unifying mechanism in the initiation of cancer and other diseases by catechol quinones. Ann N Y Acad Sci 2004;1028:247-57.
8. Bolton JL, Pisha E, Zhang F, Qiu S. Role of quinoids in estrogen carcinogenesis. Chem Res Toxicol 1998;11:1113-27.
9. Liehr JG, Ulubelen AA, Strobel HW. Cytochrome P-450-mediated redox cycling of estrogens. J Biol Chem 1986;261:16865-70.
10. Liehr JG. Genotoxic effects of estrogens. Mutat Res 1990;238:269-76.
11. Liehr JG, Roy D. Free radical generation by redox cycling of estrogens. Free Radic Biol Med 1990;8:415-23.
12. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-Hydroxyestrone: the 'good' estrogen. J Endocrinol 1996;150 Suppl:S259-65.
13. Barnea ER, MacLusky NJ, Naftolin F. Kinetics of catechol estrogen-estrogen receptor dissociation: a possible factor underlying differences in catechol estrogen biological activity. Steroids 1983;41:643-56.
14. Van Aswegen CH, Purdy RH, Wittliff JL. Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers. J Steroid Biochem 1989;32:485-92.
15. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998;19:1-27.
16. Lottering ML, Haag M, Seegers JC. Effects of 17 β-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res 1992;52:5926-32.
17. Schutze N, Vollmer G, Tiemann I, Geiger M, Knuppen R. Catecholestrogens are MCF-7 cell estrogen receptor agonists. J Steroid Biochem Mol Biol 1993; 46:781-9.
18. Vandewalle B, Lefebvre J. Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol Cell Endocrinol 1989;61:239-46.
19. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J. Estradiol 16 α-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci U S A 1985;82:6295-9,
20. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997;6:505-9.
21. Telang NT, Suto A, Bradlow HL, Wong GY, Osborne MP. Genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. Recent Prog Horm Res 1993;48:481-8.
22. Telang NT, Suto A, Wong GY, Osborne MP, Bradlow HL. Induction by estrogen metabolite 16 α-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 1992; 84:634-8.
23. Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16 α-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci U S A 1988;85:7831-5.
24. Fowke JH, Qi D, Bradlow HL, et al. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection. Steroids 2003;68:65-72.
25. Adlercreutz H, Gorbach SL, Goldin BR, et al. Estrogen metabolism and excretion in Oriental and Caucasian women. J Natl Cancer Inst 1994;86:1076-82.
26. Meilahn EN, De Stavola B, Allen DS, et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998;78:1250-5.
27. Schneider J, Kinne D, Fracchia A, et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci U S A 1982;79:3047-51.
28. Lee AJ, Zhu BT. NADPH-dependent formation of polar and nonpolar estrogen metabolites following incubations of 17 β-estradiol with human liver microsomes. Drug Metab Dispos 2004;32:876-83.
29. Hayes CL, Spink DC, Spink BC, et al. 17 β-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U S A 1996;93:9776-81.
30. Huang Z, Guengerich FP, Kaminsky LS. 16α-Hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis 1998;19:867-72.
31. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 2003;144:3382-98.
32. Lee AJ, Conney AH, Zhu BT. Human cytochrome P450 3A7 has a distinct high catalytic activity for the 16αhydroxylation of estrone but not 17β-estradiol. Cancer Res 2003;63:6532-6.
33. Lee AJ, Kosh JW, Conney AH, Zhu BT. Characterization of the NADPH-dependent metabolism of 17β-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5. J Pharmacol Exp Ther 2001;298:420-32.
34. Martucci CP, Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther 1993;57:237-57.
35. Yamazaki H, Shaw PM, Guengerich FP, Shimada T. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol 1998;11:659-65.
36. Shou M, Korzekwa KR, Brooks EN, et al. Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 1997;18:207-14.
37. Zhu BT, Lee AJ. NADPH-dependent metabolism of 17β-estradiol and estrone to polar and nonpolar metabolites by human tissues and cytochrome P450 isoforms. Steroids 2005;70:225-44.
38. van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985;45:2900-6.
39. Castagnetta L, Granata OM, Cocciadiferro L, et al. Sex steroids, carcinogenesis, and cancer progression. Ann N Y Acad Sci 2004;1028:233-46.
40. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med 2002;346:340-52.
41. Chatterton RT, Jr., Geiger AS, Mateo ET, Helenowski IB, Gann PH. Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: effect of oral contraceptives and hormone replacement. J Clin Endocrinol Metab 2005;90:1686-91.
42. Chatterton RT, Jr., Geiger AS, Khan SA, et al. Variation in estradiol, estradiol precursors, and estrogen-related products in nipple aspirate fluid from normal premenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13:928-35.
43. Busby WF, Jr., Ackermann JM, Crespi CL. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 1999;27:246-9.
44. Chauret N, Gauthier A, Nicoll-Griffith DA. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 1998;26:1-4.
45. Hickman D, Wang JP, Wang Y, Unadkat JD. Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 1998;26:207-15.
46. McFadyen MC, Breeman S, Payne S, et al. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem 1999;47:1457-64.
47. Moutsatsou P, Fountas L, Coulocheri S, Kassi E, Sekeris CE. The oestrogen receptor codon 10 polymorphism detected in breast cancer is also present in non-malignant cells. J Cancer Res Clin Oncol 1999;125:214-8.
48. Shimada T, Watanabe J, Kawajiri K, et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999; 20:1607-13.
49. Kisselev P, Schunck WH, Roots I, Schwarz D. Association of CYP1A1 polymorphisms with differential metabolic activation of 17β-estradiol and estrone. Cancer Res 2005;65:2972-8.
50. Badawi AF, Cavalieri EL, Rogan EG. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16α-hydroxylation of 17β-estradiol. Metabolism 2001;50:1001-3.
51. Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999;57:465-80.
52. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-23.
53. Bailey LR, Roodi N, Verrier CS, et al. Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res 1998;58:65-70.
54. Dialyna IA, Arvanitis DA, Spandidos DA. Genetic polymorphisms and transcriptional pattern analysis of CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes in breast cancer. Int J Mol Med 2001;8:79-87.
55. Mitrunen K, Hirvonen A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res 2003;544:9-41.
56. Taioli E, Bradlow HL, Garbers SV, et al. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect Prev 1999;23:232-7.
57. Taioli E, Trachman J, Chen X, Toniolo P, Garte SJ. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 1995;55:3757-8.
58. De Vivo I, Hankinson SE, Li L, Colditz GA, Hunter DJ. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:489-92.
59. Dunning AM, Dowsett M, Healey CS, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004;96:936-45.
60. Rylander-Rudqvist T, Wedren S, Granath F, et al. Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis 2003;24:1533-9.
61. Saintot M, Malaveille C, Hautefeuille A, Gerber M. Interactions between genetic polymorphism of cytochrome P450-1B1, sulfotransferase 1A1, catechol-o-methyltransferase and tobacco exposure in breast cancer risk. Int J Cancer 2003;107:652-7.
62. Fishman J. Aromatic hydroxylation of estrogens. Annu Rev Physiol 1983;45:61-72.
63. El-Rayes BF, Ali S, Heilbrun LK, et al. Cytochrome p450 and glutathione transferase expression in human breast cancer. Clin Cancer Res 2003;9:1705-9.
64. Modugno F, Knoll C, Kanbour-Shakir A, Romkes M. A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat 2003;82:191-7.
65. Iscan M, Klaavuniemi T, Coban T, et al. The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue. Breast Cancer Res Treat 2001;70:47-54.
66. Schmidt R, Baumann F, Knupfer H, et al. CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. Br J Cancer 2004;90:911-6.
67. Kapucuoglu N, Coban T, Raunio H, et al. Expression of CYP3A4 in human breast tumour and non-tumour tissues. Cancer Lett 2003;202:17-23.
68. Forrester LM, Hayes JD, Millis R, et al. Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. Carcinogenesis 1990;11:2163-70.